Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma

INTRODUCTION: Recent data from the COMPARZ study seem to suggest a non-inferiority of pazopanib confronted with sunitinib in PFS and OS. We previously reported how VEGF and VEGFR polymorphisms might have a predictive role in patients treated with first-line sunitinib. Aim of our study was to investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianconi, Maristella, Faloppi, Luca, Loretelli, Cristian, Zizzi, Antonio, Giampieri, Riccardo, Bittoni, Alessandro, Andrikou, Kalliopi, Prete, Michela Del, Burattini, Luciano, Montironi, Rodolfo, Scartozzi, Mario, Cascinu, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122335/
https://www.ncbi.nlm.nih.gov/pubmed/27175586
http://dx.doi.org/10.18632/oncotarget.9229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122335/
https://www.ncbi.nlm.nih.gov/pubmed/27175586
http://dx.doi.org/10.18632/oncotarget.9229

Ejemplares similares